anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a gene for encoding a recombinant porcine circovirus type 2 (PCV2) Cap protein and an application of the gene, and belongs to the field of molecular biology. The gene for encoding the recombinant PCV2 Cap protein contains a sequence as shown in SEQ ID NO:1. The invention also provides a recombinant expression vector containing the gene, and a composition containing the recombinant PCV2 Cap protein. The composition is prepared through the following steps of: culturing recombinant bacteria, breaking to obtain a supernatant of lysate, and then purifying to obtain the composition containing the recombinant PCV2 Cap protein. According to the invention, the Cap protein encoding gene is subjected to codon optimization, so the recombinant Cap protein can be high in yield, high in efficiency and suitable for soluble expression; and the composite contains peptidoglycan anchor protein (PA), so the subsequent purification is benefited. The recombinant PCV2 Cap protein provided by the invention has good activity, and the composite containing the recombinant protein can produce high-level specific antibodies of the PCV2 after a mouse is immunized by the composite.
Teratogenic Effects: Pregnancy Category D. See ‘Warnings and Precautions’ section.

Epirubicin hydrochloride can cause fetal harm when administered to a pregnant woman. Administration of 0.8 mg/kg/day intravenously of epirubicin to rats (about 0.04 times the maximum recommended single human dose on a body surface area basis) during Days 5 to 15 of gestation was embryotoxic (increased resorptions and post-implantation loss) and caused fetal growth retardation (decreased body weight), but was not teratogenic up to this dose. Administration of 2 mg/kg/day intravenously of epirubicin to rats (about 0.1 times the maximum recommended single human dose on a body surface area basis) on Days 9 and 10 of gestation was embryotoxic (increased late resorptions, post-implantation losses, and dead fetuses; and decreased live fetuses), retarded fetal growth (decreased body weight), and caused decreased placental weight. This dose was also teratogenic, causing numerous external (anal atresia, misshapen tail, abnormal genital tubercle), visceral (primarily gastrointestinal, urinary, and cardiovascular systems), and skeletal (deformed long bones and girdles, rib abnormalities, irregular spinal ossification) malformations. Administration of intravenous epirubicin to rabbits at doses up to 0.2 mg/kg/day (about 0.02 times the maximum recommended single human dose on a body surface area basis) during Days 6 to 18 of gestation was not embryotoxic or teratogenic, but a maternally toxic dose of 0.32 mg/kg/day increased abortions and delayed ossification. Administration of a maternally toxic intravenous dose of 1 mg/kg/day epirubicin to rabbits (about 0.1 times the maximum recommended single human dose on a body surface area basis) on Days 10 to 12 of gestation induced abortion, but no other signs of embryofetal toxicity or teratogenicity were observed. When doses up to 0.5 mg/kg/day epirubicin were administered to rat dams from Day 17 of gestation to Day 21 after delivery (about 0.025 times the maximum recommended single human dose on a body surface area basis), no permanent changes were observed in the development, functional activity, behavior, or reproductive performance of the offspring.

There are no adequate and well-controlled studies of epirubicin hydrochloride in pregnant women. Two pregnancies have been reported in women taking epirubicin. A 34 year old woman, 28 weeks pregnant at her diagnosis of breast cancer, was treated with cyclophosphamide and epirubicin every 3 weeks for 3 cycles. She received the last dose at 34 weeks of pregnancy and delivered a healthy baby at 35 weeks. A second 34 year old woman with breast cancer metastatic to the liver was randomized to FEC-50 but was removed from study because of pregnancy. She experienced a spontaneous abortion. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant [see Warnings and Precautions (5.12) ].
The SARAH group will receive an exercise book containing 7 mobility exercises and 4 strength exercises that are performed using elastic materials that provide progressive degrees of resistance to movement. Patients will be guided in person by a trained professional, so that they are carried out without their presence, in the home environment, daily and monitored at periodically scheduled meetings. A total of 4 face-to-face meetings will be held during the 3-month follow-up. The SARAH group and the control group will receive information related to joint protection, use of splints, assistive devices and other general advice, as needed, will receive some booklets to reinforce the guidelines. The program will last 12 weeks, with 4 face-to-face meetings lasting 40 minutes and monitored in periodically scheduled meetings.
The investigators will enroll patients with coronary disease \>1 year after an acute coronary syndrome. Subjects will be randomized to one of two treatment plans. One plan the participant will take ticagrelor for one week, then take two weeks off with no drug (washout period), then one week of rivaroxaban. The other plan will be reverse order where the participant will take rivaroxaban for one week, then two weeks off(washout period), then one week of ticagrelor. Study drugs will be provided to participants at the start of each treatment period. Bleeding time will be determined and blood samples will be taken at four timepoints (baseline, post first drug, pre second drug, and post second drug) to measure complete blood count, CRP, and fibrin clot assessment. These are surrogate markers for safety (bleeding) and efficacy (increased thrombotic risk)
The invention provides a method of screening for agents that promote or inhibit vasculogenesis or angiogenesis. The screening methods comprise culturing mesodermal stem cells, for example, allantoic cells; contacting the mesodermal stem cells with the agent to be screened; detecting endothelial cells or endothelial stem cells in the culture; and comparing the endothelial cells or endothelial cell precursors in the culture to be screened, with the endothelial cells or endothelial cell precursors in a control culture. An increase in endothelial cells or endothelial cell precursors in the culture to be screened indicates an agent that promotes vasculogenesis or angiogenesis. A decrease in endothelial cells or endothelial cell precursors in the culture to be screened indicates an agent that inhibits vasculogenesis or angiogenesis. The present invention also provides a method of screening for an agent that stabilizes vasculature or promotes remodeling of vasculature. The present invention further provides a method of screening for genes involved in promoting or inhibiting neovascularization (i.e, vasculogenesis and/or angiogenesis). The invention further provides methods of using the identified nucleic acids or agents to promote or inhibit vasculogenesis or angiogenesis in a tumor, tissue, organ, or graft. Also provided are methods of preventing and treating neovascular-dependent diseases using agents or nucleic acids identified by the screening methods of the invention. The invention further provides a method of determining whether stem cells of unknown endothelial cell potential can be promoted to differentiate into endothelial cell precursors.
Provided is a treatment apparatus for merging gallbladder meridian and heart meridian disease, which treats the merging gallbladder meridian and heart meridian disease by medicine permeation through skin. The treatment apparatus for merging gallbladder meridian and heart meridian disease comprises foreign matter discharging barrel, medicine permeation barrel, an auxiliary barrel, an ozone generator, a supersonic generator for foreign matter discharging, a supersonic medicine-swinging machine, a supersonic generator for medicine permeation, and traditional Chinese medicine prescription for treating merging gallbladder meridian and heart meridian disease. The side of the foreign matter discharging barrel is provided with the ozone generator, the supersonic generator for foreign matter discharging, the supersonic medicine-swinging machine and the medicine permeation barrel. The ozone generator is communicated with the foreign matter discharging barrel, the medicine permeation barrel and the auxiliary barrel. The medicine permeation barrel is placed with purified water and traditional Chinese medicine soup which is produced in the supersonic medicine-swinging machine for treating the merging gallbladder meridian and heart meridian disease. The treatment apparatus for merging gallbladder meridian and heart meridian disease is advantageous in that the traditional Chinese medicine molecules will not be decomposed; sewage in the body can be removed; the merging gallbladder meridian and heart meridian disease can be treated; the treatment apparatus can be used in clinic.
Neurological disorders, including Alzheimer and Parkinson's, pose significant challenges to public health due to their complex etiologies and limited treatment options. Recent advances in research have highlighted the intricate bidirectional communication between the gut microbiome and the central nervous system (CNS), revealing a potential therapeutic avenue for neurological disorders. Thus, this review aims to summarize the current understanding of the pharmacological role of gut microbiome in neurological disorders. Mounting evidence suggests that the gut microbiome plays a crucial role in modulating CNS function through various mechanisms, including the production of neurotransmitters, neuroactive metabolites, and immune system modulation. Dysbiosis, characterized by alterations in gut microbial composition and function, has been observed in many neurological disorders, indicating a potential causative or contributory role. Pharmacological interventions targeting the gut microbiome have emerged as promising therapeutic strategies for neurological disorders. Probiotics, prebiotics, antibiotics, and microbial metabolite-based interventions have shown beneficial effects in animal models and some human studies. These interventions aim to restore microbial homeostasis, enhance microbial diversity, and promote the production of beneficial metabolites. However, several challenges remain, including the need for standardized protocols, identification of specific microbial signatures associated with different neurological disorders, and understanding the precise mechanisms underlying gut-brain communication. Further research is necessary to unravel the intricate interactions between the gut microbiome and the CNS and to develop targeted pharmacological interventions for neurological disorders.
PURPOSE:To obtain a compsn. being useful as an anticancer substance having an anticancer action on cancerous cells of a human body, especially on glandular cancers such as cancer of the stomach, cancer of the lung and cancer of the pancreas and malignant tumor and a nutritional supplemental food for unsatd. fatty acid. CONSTITUTION:The compsn. contains a 2-26C composite unsatd. fatty acid wherein an unsatd. fatty acid obtd. from a liver extract of deep-sea fishes of the families gadidae, Lophiidae and Pleuronectidae is a main ingredient.
Keratoconus (KC) is a complex corneal disorder with a well-recognized genetic component. In this study, we aimed to expand the genetic spectrum of 200 Chinese patients with keratoconus and their unaffected parents. Trio-based whole-exome sequencing was performed in 200 patients with sporadic keratoconus and their unaffected parents. The variants identified in candidate genes for keratoconus were analyzed using multiple bioinformatics tools. Finally, we identified 7 variants in 5 candidate genes for keratoconus in 5 patients. The c.T464C variant in the IMPDH1 gene was defined as likely pathogenic according to the guidelines of the American College of Medical Genetics and Genomics, and the remaining variants in candidate genes (TRANK1, SLC4A11, CERKL, IFT172) were defined as uncertain significance. Our results expand the genetic spectrum in KC, highlight the genetic heterogeneity of this disease and provide important clues for future functional validation.
The invention relates to a super paramagnetic iron oxide (SPIO) marked cell for magnetic-resonance tracing in vivo. The cell can produce a strong magnetic resonance signal and be traced for a long time. A cell for the preparation of the SPIO marked cell utilized for magnetic-resonance tracing in vivo is a cell with a high ferritin expression level. The SPIO marked cell is prepared from a SPIO and a cell with a high ferritin expression level by co-culture, wherein a concentration of the SPIO as a marker is in a range of 30 to 60 micrograms per milliliter. The cell with a high ferritin expression level is a cell transfected by ferritin gene plasmids. The preferred ferritin gene plasmids are ferritin heavy-chain whole gene plasmids. Research results confirm that through highly expressed ferritin, ferrum degraded by a SPIO is regarded as an additional ferrum source, is absorbed, and is stored in a cell; ferritin can produce an effect with the SPIO as a cell marker thus a tracing time of the SPIO in a living cell is prolonged and degraded SPIO can improve a signal intensity of a ferritin reporter gene; and through a combined use of ferritin and the SPIO, a tracing time of a living marked cell and an intensity of a magnetic-resonance signal are improved.
The occurrence of periprosthetic joint infections (PJI) after total joint replacement constitutes a great burden for the patients and the healthcare system. Antibiotic-loaded polymethylmethacrylate (PMMA) bone cement is often used in temporary spacers during antibiotic treatment. PMMA is not a load-bearing solution and needs to be replaced by a functional implant. Elution from the ultrahigh molecular weight polyethylene (UHMWPE) bearing surface for drug delivery can combine functionality with the release of clinically relevant doses of antibiotics. In this study, the feasibility of incorporating a range of antibiotics into UHMWPE is investigated. Drug stability is assessed by thermo-gravimetric analysis and nuclear magnetic resonance spectroscopy. Drug-loaded UHMWPEs are prepared by compression molding, using eight antibiotics at different loading. The predicted intra-articular concentrations of drugs eluted from UHMWPE are above minimum inhibitory concentration for at least 3 weeks against Staphylococci, which are the major causative bacteria for PJI. The antibacterial efficacy is confirmed for samples covering 2% of a representative knee implant in vitro over 72 h, showing that a small fraction of the implant surface loaded with antibiotics may be sufficient against Staphylococci.
The finding of elevated troponins and regional wall motion abnormalities on echocardiography in the absence of other signs of acute coronary syndrome among the intensive care population creates a diagnostic challenge for evaluation. Sometimes these ill patients undergo invasive coronary angiography to rule out acute thrombosis. Real-Time Myocardial Perfusion Echocardiography (RTMPE) is a safe and accurate imaging modality to assess perfusion and can be performed in the resting state at the bedside in the intensive care unit (ICU) to help stratify the likelihood intracoronary thrombosis as the etiology for abnormal troponins and/or echocardiography. The primary aim of this study is to evaluate the impact of RTMPE on providers' diagnostic confidence using a 5-point Likert scale for patients that receive a standard transthoracic echocardiogram (TTE) compared to patients that receive RTMPE. The RTMPE to assess perfusion will be added to the standard transthoracic echocardiogram in approximately 24 patients undergoing evaluation of myocardial ischemia in medical or surgical ICUs. The caring provider will complete a web-based survey regarding their confidence in the diagnosis prior to and after the study in both groups. The images will be interpreted by an experienced cardiologist and results will be made available in the medical record. The difference in diagnostic confidence scores will be analyzed using the Wilcoxon signed-rank test. The secondary aims are to assess the management and outcomes in both groups.
Objective: The electronic health record (EHR) has emerged as a fundamental tool but has focused on physical care delivery. Psychosocial screenings and interventions are central to palliative care that supports whole person care models; however, EHR innovations to capture psychosocial care have not been optimized. Material and Methods: A narrative review was conducted from 2009 to March 2023. EMBASE, PubMed, and PsychINFO were queried to identify articles that discussed EHR tracking of psychosocial care in palliative care. Results: Eight articles met inclusion criteria representing a broad range of works in palliative care. Three themes emerged in the narrative review: (a) quality improvement strategy to support EHR tracking in collaboration with key stakeholders, (b) clarification of psychosocial domains for documentation and measurement, and (c) lack of standardization in data collection tools and processes. Discussion: This narrative review contributes to a limited body of literature on EHR extraction of complex sources of distress in palliative care. The designation of four domains (social history and distress, psychological symptoms, spiritual needs, and patients' goals and preferences) defines psychosocial practice aligned with palliative care quality metrics. Recommendations highlight the importance of shared priorities and collaboration with key stakeholders to fully execute on the clinical utility of EHRs. Future work will continue to evaluate data collection tools and systematic approaches to capture psychological needs and social environment and its impact on health outcomes and quality of life. Conclusion: This review will expand on opportunities for automated reporting of psychosocial care in the context of seriously ill.
BACKGROUND: The optimal revascularization strategy for non-culprit vessels is still up for debate nowadays, particularly when it comes to individuals with different Killip classes. Therefore, the aim of our study was to investigate whether multivessel revascularization, as compared with infarct-related artery (IRA) alone revascularization, improves long-term prognosis in patients who have experienced an acute myocardial infarction (AMI) and have multivessel coronary artery disease (CAD).
METHODS: A retrospective analysis was conducted on clinical data from 646 patients who presented with AMI and multivessel CAD at Beijing Chaoyang hospital between November 2014 and November 2020. Based on various revascularization strategies, patients were categorised into two groups: IRA-only revascularization (n = 416) and multivessel revascularization (n = 230). The primary endpoint was cardiovascular death.
RESULTS: In the following 60.6 months (60.6 ± 23.9), the primary endpoint occurred in 3% of the multivessel revascularization group versus 9.6% in the IRA-only revascularization group (HR 0.284, CI 0.120-0.669, p = 0.002). For the Killip I-II patients (n = 533), the primary endpoint occurred in 2.6% of the multivessel revascularization group versus 9.5% in the IRA-only revascularization group (HR 0.236, CI 0.083-0.667, p = 0.003). For Killip III-IV patients (n = 113), there was no significance differences in the primary endpoint. After using the inverse probability weighted method, the benefit of complete revascularization was consistently observed.
CONCLUSIONS: Multivessel revascularization significantly reduced the incidence of cardiovascular death for patients presenting with AMI and multivessel CAD, particularly for Killip I-II patients. There were no significant differences in the primary outcome across the groups of patients with Killip III-IV.
Pain is a complex phenomenon that involves sensory, emotional, and cognitive components. The posterior insula cortex (pIC) has been shown to integrate multisensory experience with emotional and cognitive states. However, the involvement of the pIC in the regulation of affective behavior in pain remains unclear. Here, we investigate the role of pain-related pIC neurons in the regulation of anxiety-like behavior during acute pain. We combined a chemogenetic approach with targeted recombination in active populations (TRAP) in mice. Global chemogenetic inhibition of pIC neurons attenuates chemically-induced mechanical hypersensitivity without affecting pain-related anxiety-like behavior. In contrast, inhibition of pain-related pIC neurons reduces both mechanical hypersensitivity and pain-related anxiety-like behavior. The present study provides important insights into the role of pIC neurons in the regulation of sensory and affective pain-related behavior.
Tocilizumab, 20 mg/ml; 14 ml (280 mg) dissolved in 100 ml NaCl 0.9 % i.v. once.
1. A method of treating or preventing osteoporosis associated with immunosuppressive therapy comprising: administering an effective amount of an active agent, wherein an alendronate or pharamaceutically acceptable salt thereof is used as an active agent to a patient undergoing immunosuppressive therapy. 2. A method according to claim 1 wherein the patient is receiving immunosuppressive therapy in association with an organ transplant. 3. A method according to claim 1, wherein alendronate is in the form of monosodium salt trihydrate. 4. A method according to claim 3, wherein alendronate is administered in a prophylactically effective amount. 5. A method according to claim 4, wherein alendronate is administered orally. 6. A method according to claim 4 wherein alendronate is administered in a dose of from 2.5 to 50 mg per day. 7. A method according to claim 6 wherein alendronate is administered in a dose of 5 mg, 10 mg, or 20 mg per day.
The invention discloses a dental care tooth brushing powder. The dental care tooth brushing powder is prepared from eggplant roots, pyrola corbieri, cotton roots, roots or leaves of Ilex asprella (Hook. et Arn.) Champ. ex Benth., folium hibisci, airpotato yam rhizomes, all-grass of Agrimonia pilosa Ldb., rhizomes of Japanese Butterbur, radix tetrastigme, radix rubi parvifolii, henry currant roots, meadowrue roots and rhizomes, Japanese beauty-berry, nidus vespae, maltitol, ganoderma polysaccharide and chitin. The dental care tooth brushing powder contains rich cellulose and is fast in treatment effect, and the effective rate reaches up to 100%; ganoderma polysaccharide is naturally extracted and is safe, healthy and free of toxic and side effects, and the extracting rate reaches up to 26.7%; all the Chinese herbs are extracted and purified multiple times, and the yield is increased by 15.6%; the dental care tooth brushing powder has a faint scent and slight sweet taste, is easy to use, and can eliminate peculiar oral smells, fight bacteria and diminish inflammation, suppress dental plaques, prevent decayed teeth, whiten teethes, relieve periodontal diseases, prevent hemodia, relieve gomphiasis and falling, enhance the body immunity and prevent other diseases, a patient does not have the repugnance as no peculiar traditional Chinese medicine smell exists, and dental care can be carried out while the teeth are brushed.
Subjects will have a screening visit within 30 days prior to the first dose of study drug, three treatment periods, and a follow-up visit 7-14 days after the last dose of study drug. Subjects enrolled in Arm 1 will receive GSK1349572 50 mg once daily for 7 days, GSK1348572 50 mg twice daily for 7 days, and GSK1349572 50 mg twice daily in combination with rifampin 600 mg once daily for 14 days.